Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/?d=1Neue Studien: Europe PMCdeEfficacy and drug survival after transitioning to IL-17 inhibitors in patients with psoriasis who did not respond to IL-23 inhibitors: analysis from the BIOREP registry.https://www.psoriasis-news.de/articles.html/1_articles/efficacy-and-drug-survival-after-transitioning-to-il-17-inhibitors-in-patients-with-psoriasis-who-did-not-respond-to-il-23-inhibitors-analysis-from-the-biorep-registry-r668/IntroductionSwitching biologics for psoriasis is common; however, data on switching to alternative treatments after failure of IL-23 inhibitors are limited.

Methods

A retrospective analysis was conducted to extract efficacy and drug survival data from the BIOREP registry from January 2015 to June 2025. The analysis included all patients with psoriasis who were switched from an IL-23 inhibitor to an IL-17 inhibitor during this period and had at least one follow-up visit recorded.

Results

A total of 102 patients were switched from an IL-23 inhibitor to an IL-17 inhibitor, with 92 (90.2%) of these switches occurring due to insufficient efficacy. In these 92 patients, PASI-75 was achieved in 82.6% after 3 months and in 73.5% after 12 months. Absolute PASI ≤ 1 was achieved by 66.3% of patients after 3 months and 52.9% after 12 months. Patients treated with bimekizumab had the highest probability of meeting both efficacy parameters, particularly an absolute PASI ≤ 1 after 3 months. The overall survival probability was 79.5% after 12 months and 68.1% after 24 months.

Conclusion

For patients with an inadequate response to IL-23 inhibitors, switching to IL-17 inhibitors offers adequate efficacy in reaching current therapeutic goals during the first year of treatment.

Weiterlesen

]]>668Mon, 13 Jul 2026 15:14:22 +0000Can Systemic Treatment for Childhood Psoriasis Be Stopped in Cases of Remission? Data From the ACMe Cohort.https://www.psoriasis-news.de/articles.html/1_articles/can-systemic-treatment-for-childhood-psoriasis-be-stopped-in-cases-of-remission-data-from-the-acme-cohort-r667/BackgroundIn childhood, moderate-to-severe psoriasis often requires systemic treatments such as acitretin, methotrexate, or cyclosporine. This study aimed to explore the feasibility of discontinuing systemic therapy in pediatric patients who achieve remission when receiving these treatments and to identify predictors of sustained remission.

Methods

The ACMe cohort study was a retrospective, multicenter, international, real-world study involving children and adolescents with moderate-to-severe psoriasis treated with acitretin, methotrexate, or cyclosporine. Patients who achieved remission and stopped their systemic treatment were monitored for up to 6 months to evaluate the need for further systemic treatment.

Results

Of the 433 patients analyzed, 79 (18.2%) discontinued systemic treatment due to remission. Of these, 70 (88.6%) remained off systemic treatment for at least 6 months. Factors predictive of discontinuation due to remission included younger age (9.0 ± 3.5 vs. 10.5 ± 4.1 years, p < 0.001); lower baseline psoriasis severity (PGA: 3.0 ± 0.7 vs. 3.3 ± 0.8; and PASI: 9.3 ± 4.8 vs. 11.1 ± 6.8, p < 0.04); and the presence of non-palmoplantar forms of psoriasis (palmoplantar psoriasis: 5 (6.3%) vs. 58 (16.4%), p = 0.02). No factors were identified that predicted sustained remission at 6 months.

Conclusions

These promising results suggest that systemic treatment discontinuation during clinical remission is feasible for pediatric patients with moderate-to-severe psoriasis and is associated with a low risk of early relapse. Prospective studies with long-term follow-up are needed to confirm the durability of remission and to better define criteria for selecting candidates for treatment discontinuation.

Weiterlesen

]]>667Mon, 13 Jul 2026 15:14:22 +0000Sámi psoriatic arthritis patients in northern Norway receive less conventional synthetic disease-modifying anti-rheumatic drug treatment and have more arthritis, axial symptoms, and joint damage.https://www.psoriasis-news.de/articles.html/1_articles/s%C3%A1mi-psoriatic-arthritis-patients-in-northern-norway-receive-less-conventional-synthetic-disease-modifying-anti-rheumatic-drug-treatment-and-have-more-arthritis-axial-symptoms-and-joint-damage-r666/ObjectivesTo compare Sámi and non-Sámi patients with psoriatic arthritis (PsA) and evaluate potential differences in treatment and joint damage.

Method

A total of 424 adult PsA patients meeting the ClASsification for Psoriatic ARthritis (CASPAR) criteria were recruited from the Norwegian Arthritis Registry and hospitals in northern Norway. A questionnaire from the SAMINOR (a study in regions with Sámi and Norwegian populations) was used to identify Sámi and non-Sámi patients. Demographic and clinical characteristics, joint damage, and disease-modifying anti-rheumatic drug treatment data were compared between the groups. Binary logistic regression was used to adjust for age and gender differences.

Results

Sixty Sámi and 364 non-Sámi patients were identified, and the groups were comparable in demographic characteristics and disease activity measurements. Sámi patients experienced more joint damage than non-Sámi patients (42% vs 26%, p = 0.010), and the highest rate was observed among Sámi men (p = 0.005). Sámi patients also had a higher prevalence of arthritis and axial involvement (92% vs 76%, p = 0.007 vs 32% vs 20%, p = 0.033). In addition, Sámi men showed significant underutilization of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) (83% vs 92%, p = 0.031), particularly methotrexate (68% vs 90%, p = 0.002).

Conclusion

Sámi PsA patients show higher rates of axial involvement, arthritis, and joint damage than their non-Sámi peers. Furthermore, Sámi patients demonstrate underutilization of csDMARDs. These findings underscore the importance of implementing culturally adapted healthcare strategies to improve treatment outcomes for Sámi patients with PsA.

Weiterlesen

]]>666Mon, 06 Jul 2026 17:19:47 +0000Comparative Transcriptomics Reveals SKH-1 Mice as a Valuable Model for Psoriasis Pathogenesis and Recurrence Studies.https://www.psoriasis-news.de/articles.html/1_articles/comparative-transcriptomics-reveals-skh-1-mice-as-a-valuable-model-for-psoriasis-pathogenesis-and-recurrence-studies-r665/Weiterlesen

]]>665Mon, 06 Jul 2026 17:19:47 +0000TCN2 Drives Psoriasis-Like Inflammation and Keratinocyte Hyperproliferation, Correlating With IL-1β and STAT3 Activation.https://www.psoriasis-news.de/articles.html/1_articles/tcn2-drives-psoriasis-like-inflammation-and-keratinocyte-hyperproliferation-correlating-with-il-1%CE%B2-and-stat3-activation-r664/Weiterlesen

]]>664Mon, 06 Jul 2026 17:19:47 +0000Uncovering a Dual Th17/Type 2 Transcriptomic Endotype in Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/uncovering-a-dual-th17type-2-transcriptomic-endotype-in-psoriasis-r663/BackgroundThe IL-23/Th17 axis is the cornerstone of psoriasis pathogenesis, but molecular heterogeneity across different ethnicities remains poorly defined.

Objective

To comprehensively define the immunological and pathogenic transcriptomic profiles of a Taiwanese psoriasis cohort.

Methods

Lesional skin (LS) and non-lesional skin (NL) biopsies from 11 patients with chronic plaque psoriasis and normal skin (N) from 9 healthy controls were analyzed via bulk RNA-sequencing. Differential gene expression (DEG), pathway enrichment (GSEA), and clinical correlations (PASI score) were performed. Serum levels of cytokines were validated via ELISA from all 50 psoriasis patients and 9 healthy controls.

Results

Analysis identified 4,694 DEGs in LS vs. N. We confirmed robust Th17 upregulation (IL-17A/C, IL-23A). Unanticipatedly, a profound dual immune dysregulation was identified, involving significant upregulation of Type 2 (Th2) signatures (IL-4R, CCL17, TSLP). The IL-36 family was the most highly activated cytokine axis (IL-36G log2FCH=5.5). Barrier function genes (KRT77, GJB4) were significantly downregulated. Correlation analysis identified IL-36RN and the combination of AREG/CDSN (r ≈ -0.9, p=0.002) as potential severity biomarkers.

Limitations

The small sample size and focus on a single ethnic group. Transcriptomic findings represent associations rather than mechanistic evidence of pathogenesis.

Conclusion

Taiwanese psoriasis is characterized by a dual Th17/Type 2 endotype and extreme IL-36 activation. This molecular landscape underscores the need for stratified therapeutic strategies in Taiwanese populations.

Weiterlesen

]]>663Mon, 06 Jul 2026 17:19:47 +0000A Systematic Literature Review on Methotrexate Hepatotoxicity in Psoriasis Management: Preconceived Notion or Real Threat?https://www.psoriasis-news.de/articles.html/1_articles/a-systematic-literature-review-on-methotrexate-hepatotoxicity-in-psoriasis-management-preconceived-notion-or-real-threat-r662/Weiterlesen

]]>662Mon, 06 Jul 2026 17:19:47 +0000Personalized Medicine in Psoriasis - A Long Road Ahead?https://www.psoriasis-news.de/articles.html/1_articles/personalized-medicine-in-psoriasis-a-long-road-ahead-r661/Weiterlesen

]]>661Mon, 06 Jul 2026 17:19:47 +0000Multidimensional clinical psychological and quality of life benefits of cyclosporine a therapy in patients with moderate-to-severe plaque psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/multidimensional-clinical-psychological-and-quality-of-life-benefits-of-cyclosporine-a-therapy-in-patients-with-moderate-to-severe-plaque-psoriasis-r660/Weiterlesen

]]>660Mon, 06 Jul 2026 17:19:47 +0000Pediatric psoriasis: from immunogenetics to targeted therapies.https://www.psoriasis-news.de/articles.html/1_articles/pediatric-psoriasis-from-immunogenetics-to-targeted-therapies-r659/BackgroundPediatric psoriasis may result in significant cumulative life course impairment, and there is comparatively less evidence available than for adult psoriasis.

Objective

The aim of this study is to provide an update on the management of pediatric psoriasis, integrating recent immunogenetic and therapeutic advances. It highlights challenges, including clinical heterogeneity, complex differential diagnosis, and limited treatment options, especially in Brazil.

Methods

A narrative review was conducted, including studies published in English, Portuguese, and Spanish between 2009 and 2025, retrieved from the United States National Library of Medicine (PubMed), Cochrane Library, and Scientific Electronic Library Online (SciELO). The following descriptors were used: "psoriasis", "child health", "pediatrics", "therapeutics", "comorbidity", and "T-lymphocyte antigen differentiation".

Results

Pediatric psoriasis most commonly presents as chronic plaque. Differential diagnoses are broad and include atopic dermatitis and autoimmune diseases. Data about comorbidities, particularly cardiovascular risk, are controversial. Although severe cases are less frequent, they are associated with a substantial impact on quality of life. Conventional therapies include topical corticosteroids, phototherapy, and non-targeted systemic agents such as acitretin, methotrexate, and cyclosporine. Biologic therapies have been approved for pediatric use and demonstrate safety profiles and superior efficacy compared to conventional treatments.

Study limitations

Scarcity of pediatric psoriasis guidelines.

Conclusions

Despite advances in understanding adult psoriasis, evidence in pediatric populations remains limited, especially in Brazil. Expanding knowledge in pediatric psoriasis is essential to improve diagnosis, optimize treatment strategies, and increase access to innovative therapies, thereby reducing inflammatory burden and cumulative life course impairment.

Weiterlesen

]]>659Mon, 06 Jul 2026 17:19:47 +0000Identification and experimental validation of biomarkers associated with T cell infiltration in psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/identification-and-experimental-validation-of-biomarkers-associated-with-t-cell-infiltration-in-psoriasis-r658/BackgroundPsoriasis represents a prevalent long-term inflammatory skin condition marked by the dysregulation of immune responses. T cells are integral to the pathogenesis of psoriasis. This study conducted a comprehensive analysis to recognize biomarkers associated with T cell infiltration in psoriasis and to elucidate their underlying molecular mechanisms.

Results

Three biomarkers (AKR1B10, C10orf99, and CKS2) demonstrated high sensitivity and specificity in receiver operating characteristic (ROC) curve, and the reliability of the developed nomogram diagnostic model was observed. In addition, gene set enrichment analysis (GSEA) revealed notable enrichment of the biomarkers in the NOD-like receptor signaling pathway and focal adhesion. Immune infiltration analysis indicated elevated levels of activated B cells and CD8 T cells in psoriasis samples, with the biomarkers showing meaningful correlations with the majority of immune cell infiltration statuses. Importantly, preliminary reverse transcription quantitative PCR (RT-qPCR) validation showed increased expression of AKR1B10, C10orf99, and CKS2 in psoriasis tissues, confirmed higher expression of AKR1B10, C10orf99, and CKS2 in psoriasis patients.

Conclusion

AKR1B10, C10orf99, and CKS2 may serve as candidate molecules for future mechanistic studies and provide potential diagnostic biomarkers for further investigation of psoriasis-related immune regulation.

Weiterlesen

]]>658Mon, 06 Jul 2026 17:19:47 +0000Early Response to Calcipotriol and Betamethasone Dipropionate PAD-Cream at Week 4 in Patients with Mild-to-Moderate Plaque Psoriasis: A Post-Hoc Pooled Analysis of Two Phase III Trials.https://www.psoriasis-news.de/articles.html/1_articles/early-response-to-calcipotriol-and-betamethasone-dipropionate-pad-cream-at-week%C2%A04-in-patients-with-mild-to-moderate-plaque-psoriasis-a-post-hoc-pooled-analysis-of-two-phase%C2%A0iii-trials-r657/IntroductionTopical therapy plays an essential role in psoriasis management. However, lack of rapid improvement may negatively impact adherence. The calcipotriol and betamethasone dipropionate (CAL/BDP) cream based on polyaphron dispersion (PAD) technology has demonstrated high efficacy, favorable safety, and convenience compared with CAL/BDP gel in phase III trials. This post-hoc analysis aims to assess early treatment response to CAL/BDP PAD-cream at Week (W) 4.

Methods

This was a post-hoc pooled analysis of adults with mild-to-moderate psoriasis from two multicenter, investigator-blind, phase III trials (MC2-01-C2 and MC2-01-C7). Patients were randomized 3:1:3 to CAL/BDP PAD-cream (N = 551), PAD-cream vehicle (N = 178), or CAL/BDP gel (N = 542) once daily for 8 weeks. Physician's Global Assessment (PGA) and Subject's Global Assessment (SGA) were assessed at W1 and W4. At W4, early responders were defined as patients achieving PGA controlled disease (i.e., any improvement from baseline to a PGA score of 0-1), while PGA success was defined as a PGA score of 0-1 combined with a minimum 2-point improvement from baseline. SGA controlled disease and SGA success were also assessed. Comparisons between groups were performed by logistic regression models using multiple imputation. Rates of PGA/SGA concordance were assessed by simple percent agreement.

Results

At W4, CAL/BDP PAD-cream was associated with a significantly higher proportion of patients achieving early response compared with CAL/BDP gel (32.1% vs 21.4%, P < 0.0001). Differences were already significant at W1 (7.8% vs 4.8%, P = 0.0410). PGA success at W4 was also higher with CAL/BDP PAD-cream than with CAL/BDP gel (23.6% vs 14.8%, P < 0.0001). Rates of SGA controlled disease and success were also statistically significantly higher for CAL/BDP PAD-cream at W4. Concordance between PGA/SGA assessments at W4 was observed in 65.5% (controlled disease) and 69.5% (success) of patients treated with CAL/BDP PAD-cream.

Conclusion

CAL/BDP PAD-cream was associated with significantly higher early response rates at W4 than CAL/BDP gel, suggesting earlier clinical improvements.

Weiterlesen

]]>657Fri, 03 Jul 2026 07:03:51 +0000Modified Delphi Consensus Recommendations for the Management of Psoriasis in Asia-Pacific.https://www.psoriasis-news.de/articles.html/1_articles/modified-delphi-consensus-recommendations-for-the-management-of-psoriasis-in-asia-pacific-r656/IntroductionPsoriasis imposes a substantial clinical and quality-of-life burden across the Asia-Pacific (APAC) region. Despite advances in systemic therapies, variability in disease severity classification, assessment tools, and treatment escalation criteria continues to contribute to undertreatment and delayed access to effective care.

Methods

A modified Delphi panel was conducted to develop APAC-contextualised consensus recommendations for psoriasis management. Statements were generated from a literature review and refined through Steering Committee interviews and review. The steering committee (n = 6) and Delphi panellists (n = 12) was comprised of dermatology experts from six APAC markets (Australia, China, Japan, South Korea, Malaysia, Taiwan). Consensus was generated through two structured online voting rounds involving all panellists, followed by a moderated consensus meeting, involving only the steering committee, to deliberate on any remaining non-consensus items. Consensus was defined a priori as ≥ 75% agreement among panellists.

Results

In rounds 1 and 2, 92/130 (71%) and 17/24 (71%) statements achieved consensus, respectively. Eight statements were discussed during the steering committee meeting, during which consensus was reached on all eight. In total, 121 statements achieved formal consensus, which includes an additional 4 non-consensus statements from round 1 that were retained in the final recommendations based on steering committee determination of clinical relevance. Recommendations focused on severity classification and assessment thresholds, treatment goals and response criteria, and systemic therapy eligibility and escalation.

Conclusion

These Delphi-derived recommendations provide a practical, patient-centred framework to standardise psoriasis assessment and guide timely treatment escalation in APAC. Adoption may reduce variability in care, support equitable access to appropriate systemic therapies, and improve outcomes across diverse APAC health systems.

Weiterlesen

]]>656Fri, 03 Jul 2026 07:03:51 +0000Topical ronomilast alone or combined with clobetasol ameliorates imiquimod-induced psoriasis in mice.https://www.psoriasis-news.de/articles.html/1_articles/topical-ronomilast-alone-or-combined-with-clobetasol-ameliorates-imiquimod-induced-psoriasis-in-mice-r655/Weiterlesen

]]>655Fri, 03 Jul 2026 07:03:51 +0000Integrated Cytokine Network Profiling Reveals Synergistic Inflammatory Clusters Associated with PASI Severity in Psoriasishttps://www.psoriasis-news.de/articles.html/1_articles/integrated-cytokine-network-profiling-reveals-synergistic-inflammatory-clusters-associated-with-pasi-severity-in-psoriasis-r654/Psoriasis is a chronic immune-mediated disease driven by interacting pro-inflammatory, angiogenic, and regulatory cytokine pathways. While individual cytokines of the IL-23/Th17 and Th1 axes have been widely studied, less is known about how multiple mediators behave collectively in relation to clinical severity. This study evaluated the integrated serum profile of IL-17A, IL-22, TNF-α, VEGF-A, IL-12(p40), and IL-10 in 34 patients with chronic plaque psoriasis and 19 matched healthy controls, and examined their associations with the Psoriasis Area and Severity Index (PASI). Psoriasis patients showed significantly elevated IL-17A, IL-22, TNF-α, VEGF-A, and IL-12(p40), whereas IL-10 displayed inverse pattern. Hierarchical clustering revealed a tightly interconnected pro-inflammatory cytokine network in untreated patients, with IL-17A, IL-22, and TNF-α forming a core synergistic cluster strongly associated with PASI. Systemic therapy reduced PASI and significantly decreased IL-17A, IL-22, IL-12(p40), and VEGF-A, accompanied by partial normalization of cytokine correlations. ROC analysis identified IL-22 and IL-12(p40) as potential biomarkers of treatment response. These findings demonstrate that psoriasis severity reflects coordinated activity across multiple immune pathways. Integrated cytokine profiling offers a more comprehensive understanding of disease biology and may support development of multi-marker tools for monitoring disease activity and guiding personalized therapy.

Weiterlesen

]]>654Fri, 03 Jul 2026 07:03:51 +0000Lower CALLY index values are associated with higher disease activity in psoriatic arthritis: a retrospective cohort study.https://www.psoriasis-news.de/articles.html/1_articles/lower-cally-index-values-are-associated-with-higher-disease-activity-in-psoriatic-arthritis-a-retrospective-cohort-study-r653/Weiterlesen

]]>653Fri, 03 Jul 2026 07:03:51 +0000Molecular dissection of CD28-associated cytokine signaling in early psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/molecular-dissection-of-cd28-associated-cytokine-signaling-in-early-psoriasis-r652/BackgroundPsoriasis is a chronic immune-mediated skin disorder characterized by excessive keratinocyte proliferation and abnormal T-cell activation. Cluster of Differentiation 28 (CD28), a costimulatory protein, plays a crucial role in psoriasis pathophysiology by enhancing T-cell activation and promoting cytokine release.

Methods

A case-control study was involving 168 newly diagnosed psoriasis patients and 159 healthy control individuals (HC), Genotyping of rs1879877 in promoter of CD28 gene was performed using the tetra-primer amplification refractory mutation system-polymerase chain reaction (T-ARMS-PCR), and serum levels of soluble CD28 (sCD28) and selected cytokines (Interleukin (IL), IL-38, IL-39 and Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)) were measured using sandwich enzyme-linked immunosorbent assay (ELISA).

Results

The heterozygous GT genotype was predominant among psoriasis patients and was significantly associated with elevated serum sCD28 levels compared to controls, who predominantly carried the wild type GG genotype. Elevated sCD28 levels were linked to increased T-cell activation, contributing to immune dysregulation and disease severity. This was evidenced by increased production of pro-inflammatory cytokines, including IL-39 and GM-CSF, with a concurrent decrease in the anti-inflammatory cytokine IL-38.

Conclusion

Serum sCD28 levels were significantly elevated in psoriasis patients. The CD28 gene variant rs1879877 (-1198 G/T) appears to be associated with psoriasis pathogenesis, potentially due to increased transcriptional activity that elevates sCD28 expression, thereby influencing T-cell activation and immune modulation.

Weiterlesen

]]>652Fri, 03 Jul 2026 07:03:51 +0000Biologic therapies in pediatric psoriasis: A single-center experience.https://www.psoriasis-news.de/articles.html/1_articles/biologic-therapies-in-pediatric-psoriasis-a-single-center-experience-r651/Weiterlesen

]]>651Fri, 03 Jul 2026 07:03:51 +0000Clinical Characteristics, Healthcare Resource Utilization, and Costs of Patients with Generalized Pustular Psoriasis in Taiwan: A National Claims Database Study.https://www.psoriasis-news.de/articles.html/1_articles/clinical-characteristics-healthcare-resource-utilization-and-costs-of-patients-with-generalized-pustular-psoriasis-in-taiwan-a-national-claims-database-study-r650/BackgroundGeneralized pustular psoriasis (GPP) is a rare and severe inflammatory disease characterized by widespread pustular eruptions and systemic inflammation.

Objective

To evaluate the clinical characteristics and disease burden of patients with GPP in Taiwan using a national claims database.

Methods

Patients with GPP and no prior diagnosis of psoriasis vulgaris (PV) who experienced an incident flare between January 1, 2017, and September 30, 2020, were identified from Taiwan's National Health Insurance Database. Clinical characteristics, comorbidities, and treatment patterns were described. Recurrent flare frequency, healthcare resource utilization (HCRU) and costs were compared with those of a propensity score-matched PV cohort at a ratio of up to 1:4. Outpatient-managed flares were classified as moderate, whereas hospitalized flares were classified as severe.

Results

A total of 245 patients with GPP were included (mean age 51.3 years; 49.8% male). During follow-up, 1,156 moderate-to-severe flares were identified. Compared with matched patients with PV, patients with GPP had a higher recurrent flare rate (rate ratio 1.14; 95% CI 1.06-1.23). Patients with GPP also had greater HCRU, including more outpatient visits (incidence rate ratio [IRR] 1.03 [95% CI 1.01-1.05]), emergency room visits (IRR 1.33, 95% CI 1.19-1.49), and hospital admissions (IRR 1.69 [1.50-1.91]). Median monthly healthcare costs were approximately twice as high among patients with GPP as among matched patients with PV.

Conclusion

Patients with GPP experienced recurrent flares, greater healthcare utilization, and higher healthcare costs than matched patients with PV, underscoring the substantial real-world clinical and economic burden of GPP.

Weiterlesen

]]>650Fri, 03 Jul 2026 07:03:51 +0000Real-World Effectiveness of Tildrakizumab in Japanese Patients With Psoriasis: Analyses Stratified by Prior Systemic Therapy, Maintenance of Early Responses, and Achievement of Delayed Responses.https://www.psoriasis-news.de/articles.html/1_articles/real-world-effectiveness-of-tildrakizumab-in-japanese-patients-with-psoriasis-analyses-stratified-by-prior-systemic-therapy-maintenance-of-early-responses-and-achievement-of-delayed-responses-r649/Weiterlesen

]]>649Fri, 03 Jul 2026 07:03:51 +0000Two-dimensional GeTe nanosheets for psoriasis through modulation of macrophage activation and psoriatic inflammation.https://www.psoriasis-news.de/articles.html/1_articles/two-dimensional-gete-nanosheets-for-psoriasis-through-modulation-of-macrophage-activation-and-psoriatic-inflammation-r648/In vivo, the oral administration of GeTe-NSs in an IMQ-induced psoriasis mouse model resulted in significant improvements in clinical scores, epidermal thickening, and the proportions of M1/M2 macrophages in spleen and skin lesions. Taken together, these findings suggest that GeTe-NSs could be a promising nanomaterial for treating inflammatory diseases, including psoriasis.

Weiterlesen

]]>648Fri, 03 Jul 2026 07:03:51 +0000<![CDATA[Extracellular vesicles as biomarkers for psoriatic arthritis: a systematic review & meta-analysis]]>https://www.psoriasis-news.de/articles.html/1_articles/extracellular-vesicles-as-biomarkers-for-psoriatic-arthritis-a-systematic-review-meta-analysis-r647/Background Psoriatic arthritis (PsA) is an inflammatory condition involving joints, tendon-bone entheses and synovium that can develop in individuals with psoriasis. Early, accurate clinical diagnosis remains difficult. Extracellular vesicles (EVs) carry proteins and miRNAs that

Methods

PubMed and Embase were searched from inception through May 21st, 2026, and human studies examining EV-associated protein or miRNA biomarkers in PsA and related psoriatic or inflammatory diseases were included, with risk of bias assessed using a modified Newcastle-Ottawa Scale and diagnostic accuracy summarized using HSROC/BRMA models when data were sufficient.

Results

Seven studies met the inclusion criteria, including 119 individuals with PsA (weighted mean age: 49.8 years; 43.7% female), 205 individuals with non-PsA psoriasis (weighted mean age: 46.4 years; female %: NA), 55 controls (weighted mean age: 44.5 years; 38.2% female), and 50 individuals with other inflammatory joint disorders (weighted mean age: 58.0 years; 58.0% female). EV-associated protein markers demonstrated heterogeneous findings related to immune, vascular, inflammatory, and osteoimmunological signaling. Only 4.2% (4/95) of miRNAs were consistently identified across studies comparing PsA with non-PsA psoriasis, with lower overlap (1.5%, 1/67) in studies comparing PsA with controls. ROC meta-analysis suggested preliminary diagnostic potential, particularly for distinguishing PsA from non-PsA psoriasis, although evidence was constrained by small study numbers.

Conclusions

EV-associated proteins and miRNAs are potential biomarker candidates for PsA, reflecting inflammatory, vascular, and osteoimmunological processes underlying disease pathophysiology. However, current evidence remains preliminary and limited by small cohorts, methodological heterogeneity, and inconsistent reporting across studies.

Weiterlesen

]]>647Mon, 29 Jun 2026 08:21:12 +0000A Serum N-Glycan Ratio Associated With Disease Severity and Treatment Response in Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/a-serum-n-glycan-ratio-associated-with-disease-severity-and-treatment-response-in-psoriasis-r646/Weiterlesen

]]>646Mon, 29 Jun 2026 08:21:12 +0000Exploring the Gut Microbiome's Association in Psoriasis and Psoriatic Arthritis: A Scoping Review.https://www.psoriasis-news.de/articles.html/1_articles/exploring-the-gut-microbiomes-association-in-psoriasis-and-psoriatic-arthritis-a-scoping-review-r645/IntroductionPsoriasis (PsO) and psoriatic arthritis (PsA) are chronic inflammatory conditions treated with primarily immune-modulating medication. However, interest is growing in gut microbiome therapies. Studies have reported altered gut microbiota in PsO/PsA and explored probiotics and fecal microbiota transplantation (FMT) as potential therapies. This review synthesizes global studies on the microbiome's associations in PsO/PsA.

Methods

We conducted a scoping literature review to understand the association between gut microbiota in PsO and PsA patients. Pubmed was used to identify 4,126 published manuscripts between 2015-2025. Thirty studies were included, encompassing 749,275 participants, with balanced gender representation and ages ranging from 18 to 76 years. These studies included 21 case-control studies, 1 case-series, 2 genome-wide analyses, 5 clinical trials, and 1 retrospective review.

Results

Eighteen studies reported significant gut microbiome differences in PsO/PsA vs healthy controls. Variation in the Firmicutes/Bacteroides (F/B) ratio was of interest, with one study suggesting a low F/B ratio and five studies suggesting an elevated F/B ratio in PsO. A higher F/B ratio was linked to increased acetate production. Acetate and propionate, key short-chain fatty acids (SCFAs), were associated with modulation of the IL-23/Th17 axis in psoriasis and activation of keratinocytes. The role of therapeutics targeting the gut microbiome was explored. Ustekinumab and tofacitinib altered gut microbiome composition. Probiotic and FMT interventions showed mixed outcomes. Six of eight probiotic studies reported increased SCFA producing species and/or reduced inflammatory markers. FMT improved immune markers in mice but had no significant benefit in human trials.

Conclusion

Alterations in the microbiome linked to inflammation and immune response, suggest the microbiome as a potential therapeutic target for PsO/PsA.

Weiterlesen

]]>645Mon, 29 Jun 2026 08:21:12 +0000A cohort study of obese patients with moderate-to-severe psoriasis using biological medicines in Catalonia, Spain.https://www.psoriasis-news.de/articles.html/1_articles/a-cohort-study-of-obese-patients-with-moderate-to-severe-psoriasis-using-biological-medicines-in-catalonia-spain-r644/Weiterlesen

]]>644Mon, 29 Jun 2026 08:21:12 +0000